News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
New and experimental hepatitis C treatment
Hep C quad regimens quashed, but some components go forward

A pair of four-drug interferon-based hepatitis C regimens worked well, but further study has been halted after a few patients experienced serious adverse events, according to a

Published
29 April 2013
By
Liz Highleyman
New and experimental hepatitis C treatment
Daclatasvir + sofosbuvir offers hepatitis C rescue therapy after current standard of care

An interferon-free regimen of daclatasvir plus sofosbuvir, with or without ribavirin, cured all previously treated hepatitis C (HCV) patients who did not respond to interferon-based triple therapy

Published
29 April 2013
By
Liz Highleyman
Hepatitis C transmission and prevention
HIV warning over illegal tattooists

Illegal unlicensed tattoo parlours are putting customers at risk of contracting HIV and hepatitis, council bosses warn.

Published
28 April 2013
From
BBC Health
New and experimental hepatitis C treatment
Gilead-Bristol Hepatitis C Combo Cures 100% of Patients in Study

A combination of hepatitis C drugs from Gilead Sciences Inc. (GILD) and Bristol-Myers Squibb Co. (BMY) cured 100 percent of patients in a trial, showing the success of a cocktail that doctors say they want yet may never be approved.

Published
28 April 2013
From
Businessweek
New and experimental hepatitis C treatment
AbbVie interferon-free combination cures over 90% of hepatitis C genotype 1

A four-drug combination of direct acting antivirals developed by AbbVie cured hepatitis C infection in over 90% of participants in the AVIATOR study, without the need for

Published
26 April 2013
By
Keith Alcorn
New and experimental hepatitis C treatment
Sofosbuvir + ribavirin cures most genotype 2 hepatitis C, but genotype 3 response is lower

A dual oral regimen containing the hepatitis C nucleotide polymerase inhibitor sofosbuvir plus ribavirin produced high sustained virological response rates overall, but this was driven by very

Published
26 April 2013
By
Liz Highleyman
New and experimental hepatitis C treatment
Sofosbuvir Offers High Cure Rate For Two Hepatitis C Subtypes -

Sofosbuvir, a new drug, is offering impressive cure rates for Hepatitis C patients with two subtypes of the disease - genotypes 2 and 3, according to researchers led by Weill Cornell Medical College.

Published
24 April 2013
From
Medical News Today
New and experimental hepatitis C treatment
Investigational compound faldaprevir shows high viral cure and early treatment success in treatment-naïve patients with genotype-1 hepatitis C

In the Phase III clinical trial STARTVerso™1, up to 80% of patients treated with faldaprevir+ and PegIFN/RBV achieved viral cure (SVR12).

Published
24 April 2013
From
Boehringer-Ingelheim press release
New and experimental hepatitis C treatment
Medivir: New Data from Simeprevir Phase III Studies Quest 1 and 2 in Hepatitis C Patients will be Presented at EASL 23-28 April in Amsterdam Read more: Medivir: New Data from Simeprevir Phase III Studies Quest 1 and 2 in Hepatitis C Patients will be Pres

These primary efficacy and safety results from two global phase III studies demonstrate that use of the investigational protease inhibitor simeprevir led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 80 and 81 percent, respectively, of treatment-naïve genotype 1 chronic hepatitis C adult patients with compensated liver disease, when administered once daily with pegylated interferon and ribavirin.

Published
24 April 2013
From
Medivir press release
New and experimental hepatitis C treatment
Bristol-Myers oral hepatitis C regimen looks competitive -study

The combination therapy, which involves three direct acting antiviral drugs that each attack different targets needed for replication of the hepatitis virus, achieved cure rates as high as 94 percent when given for either 12 weeks or 24 weeks, according to results of the small study.

Published
24 April 2013
From
Reuters
← Prev12345...103Next →

Filter by country